← FDA DRUG APPROVALS

FDA ANDA · ANDA078558

IBUPROFEN

Sponsor: AMNEAL PHARMS NY

APPLICATION
ANDA078558
TYPE
ANDA
ORIGINAL APPROVAL
2007-06-18
LATEST ACTION
2024-11-21
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

IBUPROFENPrescription
IBUPROFEN 800MG · TABLET · ORAL
IBUPROFENPrescription
IBUPROFEN 400MG · TABLET · ORAL
IBUPROFENPrescription
IBUPROFEN 600MG · TABLET · ORAL

Approval history

2024-11-21Labeling · Supplement 41 · standardAP
2024-11-18Labeling · Supplement 36 · standardAP
2021-04-28Labeling · Supplement 32 · standardAP
2019-07-22Labeling · Supplement 27 · standardAP
2016-05-09Labeling · Supplement 20 · standardAP
2011-11-07Manufacturing (CMC) · Supplement 11AP
2007-12-26Labeling · Supplement 3AP
2007-06-18OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →